



## **Richard Finn**

### **CURRENT POSITIONS**

Associate Professor of Medicine, Geffen School of Medicine at UCLA

Co-Director, Signal Transduction and Therapeutics Program  
Geffen School of Medicine at UCLA

### **EDUCATIONAL AND CAREER EXPERIENCES**

- UCLA- Biochemistry, BS
- University of Southern California, MD
- UCLA Medical Center, Internal Medicine and Hematology/ Oncology

### **PUBLICATION**

- Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. *Nat Rev ClinOncol*. 2015 Jun 23.
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Dela Cruz C, Poulart V, Wang JH. *Hepatology*. 2014 Nov;60(5):1697-707.
- A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Zhu AX, Finn RS, Mulcahy M, et al. *Clin Cancer Res*. 2013 Dec 1;19(23):6614-23.
- Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. *J ClinOncol*. 2013 Oct 1;31(28):3509-16
- Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Finn RS, Poon RT, Yau T, Klumpen HJ, et al. *JHepatol*. 2013 Dec;59(6):1271-7.

### **AWARDS AND HONORS**

President, International Liver Cancer Association (Sept 2015)